Related Experiment Video

Updated: May 10, 2025

Yeast As a Chassis for Developing Functional Assays to Study Human P53
14:57

Yeast As a Chassis for Developing Functional Assays to Study Human P53

Published on: August 4, 2019

9.5K

Strategies for p53 Activation and Targeted Inhibitors of the p53-Mdm2/MdmX Interaction

Ye Huang1, Wang Li1, Yuke Zhou1

  • 1Institute of Modern Fermentation Engineering and Future Foods, School of Light Industry and Food Engineering, Guangxi University, No. 100, Daxuedong Road, Nanning 530004, China.

Cells
|April 25, 2025
PubMed

Insights

Targeting the p53-Mdm2/MdmX interaction is crucial for cancer therapy. Inhibitors blocking Mdm2 and MdmX can restore tumor suppressor p53 activity, offering a promising strategy against cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • The p53 tumor suppressor gene is vital for preventing cancer.
  • Mdm2 and MdmX proteins negatively regulate p53, often overexpressed in cancers.
  • Mdm2 targets p53 for degradation, inhibiting its tumor-suppressive function.

Purpose of the Study:

  • To review the regulatory relationship between p53, MdmX, and Mdm2.
  • To summarize the current landscape of p53-Mdm2/MdmX inhibitors.
  • To provide a foundation for developing novel targeted cancer therapies.

Main Methods:

  • Literature review of p53, Mdm2, and MdmX interactions.
  • Analysis of current therapeutic strategies targeting these proteins.
  • Discussion of the implications for cancer drug discovery.

Main Results:

  • Overexpression of Mdm2 and MdmX frequently inactivates p53 in cancer.
  • Inhibition of p53-Mdm2/MdmX interaction is a validated anti-cancer approach.
  • Various inhibitors targeting these interactions are under investigation.

Conclusions:

  • Restoring wild-type p53 function by blocking Mdm2/MdmX is a key strategy in cancer treatment.
  • Further research into p53-Mdm2/MdmX inhibitors is essential for future drug development.
  • Understanding these regulatory pathways offers significant therapeutic potential for numerous cancers.
Keywords:
Mdm2MdmXcancerinhibitorsp53

More Related Videos

Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay05:17

Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay

Published on: February 9, 2021

1.4K
Purification of Ubiquitinated p53 Proteins from Mammalian Cells10:55

Purification of Ubiquitinated p53 Proteins from Mammalian Cells

Published on: March 21, 2022

2.0K

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.3K
DNA Damage can Stall the Cell Cycle02:37

DNA Damage can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
9.0K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
35.0K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
5.6K